Longboard Pharmaceuticals' Presence At American Epilepsy Society Annual Meeting Reinforces Ongoing Commitment To The Rare Epilepsy Community
Portfolio Pulse from Benzinga Newsdesk
Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) is presenting new data on LP352, a treatment for seizures associated with Developmental and Epileptic Encephalopathies (DEEs), at the 2023 AES Annual Meeting. The company is showcasing posters on LP352's drug interactions, pharmacokinetics, and pharmacodynamics, and hosting a scientific exhibit to discuss the ongoing PACIFIC study and Phase 3 program plans. Dr. Randall Kaye highlighted LP352's potential as a best-in-class therapy and Longboard's commitment to advancing treatment for rare seizure disorders.
November 21, 2023 | 9:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Longboard Pharmaceuticals is presenting promising data on LP352 at the AES Annual Meeting, indicating potential as a best-in-class therapy for DEEs. The company's commitment to advancing treatment for rare seizure disorders is reinforced through scientific exhibits and collaborations.
The presentation of favorable data for LP352 at a major conference could positively influence investor perception and raise expectations for the drug's success. The focus on LP352's potential as a best-in-class therapy for DEEs and the upcoming topline data from the PACIFIC study in January 2024 may increase investor interest and optimism in the short term.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 90